Objective  To explore the effect of etoricoxib combined with Bitong decoction formula on the clinical efficacy and serum level of patients with knee osteoarthritis.

Methods  Retrospective analysis was used to collect patients with knee osteoarthritis admitted to our hospital from August 2022 to August 2023. According to the medication method, they were divided into the combined group and the control group. The control group was given etoricoxib tablets, and the combination group was given a combination of Bitong decoction formula on the basis of the control group. Both groups were treated for one month. The efficacy after treatment, Traditional Chinese Medicine (TCM) syndrome score, the knee joint function [osteoarthritis index (WOMAC), Lequesne score], inflammatory indicators [interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), matrix metalloproteinase-3 (MMP-3), tissue inhibitor of metalloproteinase-1 (TIMP-1)], oxidative stress indicators [total antioxidant capacity (TAOC), lipid peroxidation (LPO), nitric oxide (NO)] before and after treatment and safety of the two groups were compared.

Results  A total of 162 patients were included, with 81 in each group. The overall efficacy and total effective rate of the combined group were higher than those of the control group (P<0.05). After treatment, TCM syndrome score, WOMAC, Lequesne score, IL-1β, TNF-α, MMP-3, TIMP-1, LPO and NO levels in two groups were decreased compared with before treatment, while TAOC increased compared with before treatment (P<0.05), and all the above indexes in the combination group were better than those in the control group (P<0.05). The safety of the two groups was comparable (P>0.05).

Conclusion  The efficacy of etoricoxib combined with Bitong decoction formula in knee osteoarthritis is better than that of single western medicine, which can alleviate symptoms and improve knee joint function, as well as reduce inflammation and oxidative stress, and has high safety.

1.Sharma L. Osteoarthritis of the knee[J]. N Engl J Med, 2021, 384(1): 51-59. DOI: 10.1056/NEJMcp1903768.

2.He WW, Wu YJ, Liu QM, et al. Effect of etoricoxib on miR-214 and inflammatory reaction in knee osteoarthritis patients[J]. Am J Transl Res, 2021, 13(8): 9586-9592. https://pubmed.ncbi.nlm.nih.gov/34540082/.

3.姜美华, 韩志武, 徐友平, 等. 双醋瑞因联合不同剂量依托考昔治疗急性重度痛风性关节炎的回顾性临床观察[J]. 中国药师, 2022, 25(3): 486-489. [Jiang MH, Han ZW, Xu YP, et al. Retrospective clinical observation of diacerein combined with different doses of etoricoxib in the treatment of acute severe gouty arthritis[J]. China Pharmacist, 2022, 25(3): 486-489.] DOI: 10.19962/j.cnki.issn1008-049X.2022.03.019.

4.世界中医药学会联合会骨质疏松专业委员会, 上海中医药大学附属龙华医院, 中日友好医院, 等. 膝骨关节炎中西医结合诊疗专家共识[J]. 世界中医药, 2023, 18(7): 929-935. [Osteoporosis Committee of World Federation of Chinese Medicine Societies, Longhua Hospital Affiliated to Shanghai University of Chinese Medicine, China-Japan Friendship Hospital, et al. Expert consensus on the diagnosis and treatment of knee osteoarthritis with integrated traditional Chinese and western medicine[J]. World of Traditional Chinese Medicine, 2023, 18(7): 929-935.] DOI: 10.3969/j.issn.1673-7202.2023.07.007.

5.周伟, 郑红波, 冯穗, 等. 活血膏外敷联合痹痛汤方口服治疗膝骨关节炎的疗效观察及对患者炎性反应、抗氧化能力的影响[J]. 河北中医, 2023, 45(7): 1106-1110. [Zhou W, Zheng HB, Feng S, et al. Clinical efficacy of external application of Huoxue ointment combined with oral Bitong decoction for knee osteoarthritis,and its influence on inflammatory response and antioxidant capacity[J]. Hebei Journal of Traditional Chinese Medicine, 2023, 45(7): 1106-1110.] DOI: 10.3969/j.issn.1002-2619.2023.07.012.

6.韩广弢, 李皓桓, 蔡伟松, 等. 骨关节炎中的氧化应激信号通路研究进展[J]. 中国医药导报, 2020, 17(9): 29-32. [Han GT, Li HH, Cai WS, et al. Advances in oxidative stress signaling pathways in osteoarthritis[J]. China Medical Herald, 2020, 17(9): 29-32.] DOI: CNKI:SUN: YYCY.0.2020-09-009.

7.中华医学会骨科学分会关节外科学组, 中国医师协会骨科医师分会骨关节炎学组, 国家老年疾病临床医学研究中心（湘雅医院）, 等. 中国骨关节炎诊疗指南（2021年版）[J]. 中华骨科杂志, 2021, 41(18): 1291-1314. [Joint Surgery Group, Orthopaedic Branch of Chinese Medical Association, Osteoarthritis Group, Orthopaedic Branch of Chinese Medical Doctor Association, National Clinical Medical Research Center for Geriatric Diseases (Xiangya Hospital), et al. Osteoarthritis guidelines of China (2021 edition)[J]. Chinese Journal of Orthopaedics, 2021, 41(18): 1291-1314.] DOI: 10.3760/cma.j.cn121113-20210624-00424.

8.中华中医药学会骨伤科分会膝痹病（膝骨关节炎）临床诊疗指南制定工作组. 中医骨伤科临床诊疗指南·膝痹病（膝骨关节炎）[J]. 康复学报, 2019, 29(3): 1-7. [Chinese Society of Traditional Chinese Medicine Orthopedics and Traumatology Branch Knee Arthralgia (knee osteoarthritis) Clinical Guidelines Formulation Working Group. Clinical guidelines for diagnosis and treatment of knee osteoarthritis (Xibibing) in orthopedics and traumatology of traditional Chinese Medicine[J]. Rehabilitation Medicine, 2019, 29(3): 1-7.] DOI: 10.3724/SP.J.1329.2019.03001.

9.国家中医药管理局. 中药新药临床研究指导原则（试行）[S]. 北京:中国医药科技出版社, 2002: 349-353.

10.McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties[J]. Arthritis Rheum, 2001, 45(5): 453-461. DOI: 10.1002/1529-0131(200110)45:5<453::aid-art365> 3.0.co;2-w.

11.Lecorney J, Verhoeven F, Chouk M, et al. Correlation between catastrophizing and Lequesne index in case of osteoarthritis of the knee: a prospective study[J]. Joint Bone Spine, 2018, 85(5): 605-607. DOI: 10.1016/j.jbspin.2017.10.002.

12.许成燕, 陈军香, 王教明, 等. 中国人群膝骨关节炎危险因素的Meta分析[J]. 中国循证医学杂志, 2021, 21(7): 772-778. [Xu CY, Chen JX, Wang ZM, et al. The risk factors for knee osteoarthritis among Chinese population: a Meta-analysis[J]. Chinese Journal of Evidence-Based Medicine, 2021, 21(7): 772-778.] DOI: 10.7507/1672-2531.202102072.

13.刘永利, 谢芳, 戴斌玉, 等. 邵先舫教授辨证治疗膝骨关节炎临床经验[J]. 湖南中医药大学学报, 2022, 42(1): 104-108. [Liu YL, Xie F, Dai BY, et al. Professor Shao Xianfang's clinical experience in curing knee osteoarthritis based on syndrome differentiation[J]. Journal of Hunan University of Chinese Medicine, 2022, 42(1): 104-108.] DOI: 10.3969/j.issn.1674-070X.2022.01.021.

14.何冶, 洪明志, 朱小春. 非布司他联合依托考昔治疗痛风性关节炎的临床疗效分析[J]. 数理医药学杂志, 2023, 36(6): 446-451. [He Y, Hong MZ, Zhu XC. Analysis of clinical efficacy of febuxostat combined with etoricoxib in the treatment of gouty arthritis[J]. Journal of Mathematical Medicine, 2019, 36(6): 446-451.] DOI: 10.12173/j.issn.1004-4337.202302067.

15.田传玺, 张伟, 张宇昕, 等. 重构本草——熟地黄[J]. 吉林中医药, 2023, 43(5): 596-598. [Tian CX, Zhang W, Zhang YX, et al. Reconstruction of Chinese materia medica-prepared rehmannia root[J]. Jilin Chinese Medicine, 2023, 43(5): 596-598.] DOI: 10.13463/j.cnki.jlzyy.2023.05.023.

16.郝瑞, 赵旌屹, 鲍婷婷, 等. 重构本草——威灵仙[J]. 长春中医药大学学报, 2024, 40(3): 259-261. [Hao R, Zhao JY, Bao TT, et al. Reconstruction of Chinese materia medica-Chinese clematis root[J]. Journal of Changchun University of Chinese Medicine, 2024, 40(3): 259-261.] DOI: 10.13463/j.cnki.cczyy.2024.03.006.

17.王少平, 赵一慕, 李盼盼, 等. 基于网络药理学的土鳖虫破血逐瘀作用机制研究[J]. 中国现代中药, 2021, 23(3): 457-463, 469. [Wang SP, Zhao YM, Li PP, et al. Study on mechanism of blood-breaking and stasis-removing effects of Eupolyphaga steleophaga based on network pharmacology[J]. Modern Chinese Medicine, 2019, 23(3): 457-463, 469.] DOI: 10.13313./j.issn.1673-4890.20200219001.

18.王雷, 余德涛, 邢祯全. 依托考昔抑制SDF-1/CXCR4信号通路影响骨关节炎软骨细胞增殖、凋亡及炎性因子表达[J]. 现代免疫学, 2021, 41(6): 468-472. [Wang L, Yu DT, Xing ZQ. Etoricoxib affects osteoarthritis chondrocytes' proliferation, apoptosis and expression of inflammatory factors by inhibiting SDF-1/CXCR4 signaling pathway[J]. Current Immunology, 2021, 41(6): 468-472.] https://d.wanfangdata.com.cn/periodical/shmyxzz202106005.

19.安丽欣, 张倩, 李昆, 等. 基于微RNA-22-3p探讨双醋瑞因联合依托考昔治疗痛风性关节炎的作用机制[J]. 安徽医药, 2023, 27(6): 1162-1166. [An LX, Zhang Q, Li K, et al. Exploring the mechanism of diacerein combined with etoricoxib in the treatment of gouty arthritis based on microRNA-22-3p[J]. Anhui Medical and Pharmaceutical Journal, 2023, 27(6): 1162-1166.] DOI: 10.3969/j.issn.1009-6469.2023.06.023.

20.吕成龙, 李会会, 史永洁, 等. 中药当归现代研究进展及其质量标志物的预测分析[J]. 中国中药杂志, 2022, 47(19): 5140-5157. [Lyu CL, Li HH, Shi YJ, et al. Research progress of Angelicae sinensis Radix and predictive analysis on its quality markers[J]. Chinese Journal of Traditional Chinese Medicine, 2022, 47(19): 5140-5157.] DOI: 10.19540/j.cnki.cjcmm.20220225.203.

21.黄胜男, 胡元会, 张颖, 等.基于网络药理学探讨威灵仙治疗痛风的作用机制[J]. 中国药师, 2020, 23(9): 1715-1720. [Huang SN, Hu YH, Zhang Y, et al. Mechanism of Clematidis Radix et Rhizoma in the treatment of gout based on network pharmacology[J]. China Pharmacist, 2020, 23(9): 1715-1720.] DOI: 10.3969/j.issn.1008-049X.2020.09.008.